Crinetics Pharmaceuticals, Inc.
CRNX
Classifica tra le azioni
#2227
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Prezzo delle azioni
$84.95
Ultima sincronizzazione: 2026-09-01
Capitalizzazione di mercato
$9.00B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
98.25%
Paese
US
Scambia Crinetics Pharmaceuticals, Inc. (CRNX)
Categoria
Healthcare
Ricavi di Crinetics Pharmaceuticals, Inc. (CRNX)
Ricavi nel Jun 2026 TTM: $42.16M
Secondo gli ultimi rapporti finanziari di Crinetics Pharmaceuticals, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $42.16M. Nel 2023, l'azienda ha registrato ricavi di $4.01M una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $4.74M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Crinetics Pharmaceuticals, Inc. da 2016 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $42.16M | 3,957.36% |
| 2024 | $1.04M | -74.11% |
| 2023 | $4.01M | -15.28% |
| 2022 | $4.74M | 339.42% |
| 2021 | $1.08M | 1,418.31% |
| 2020 | $71.00K | -94.05% |
| 2019 | $1.19M | -50.86% |
| 2018 | $2.43M | 18.73% |
| 2017 | $2.05M | 247.20% |
| 2016 | $589.00K | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 29,846.63% |
US
|
|
| $2.23B | 5,185.13% |
US
|
|
| $15.74B | 37,247.77% |
AU
|
|
| $6.02B | 14,183.35% |
NL
|
|
| - | - |
CH
|
